Company attributes
Other attributes
Globavir Biosciences is a biopharmaceutical company creating novel therapeutics and diagnostic tool for treating infectious disease that is headquartered in Los Altos, California and was founded in 2011 by Shalabh Gupta and Vijay Pande. The company is focused on commercializing re-purposed drugs for controlling infectious diseases such as coronavirus, dengue fever, ebola, and Chikungunya. Their lead drug candidate is called GBV-006 and is a combination of two drugs approved by the FDA for affecting viral load and mortality of viral infections.
On October 17, 2016 Globavir Biosciences announced entering a partnership with Bio-Rad Laboratories to licence Globavir's PanGlob Dengue detection technology. There were no financial details of the partnership and licensing agreement between the two companies.
On November 12, 2012 Globavir Biosciences announced raising $2 million in seed funding from undisclosed investors.
On January 21, 2015 Globavir Biosciences announced raising $4 million in venture funding from StartX, Stanford University Venture Fund, and Sorrento Therapeutics.
On September 20, 2016 Globavir Biosciences announced raising $1.5 million in venture funding from undisclosed investors.
